What 北京百奥赛图基因生物技术有限公司 does

Beijing Biocytogen (北京百奥赛图基因生物技术有限公司) is a privately-held preclinical drug discovery platform founded in 2009 and headquartered in Beijing Daxing District. The company operates an integrated offering spanning gene-edited animal models, fully human antibody discovery, and preclinical pharmacology services for global pharmaceutical and biotechnology buyers. Its commercial footprint extends across China, the United States, Germany, and Japan, with localized web presences in Chinese, English, Japanese, and Korean.

The company's core technology is the proprietary SUPCE™ gene editing platform, which performs large-fragment in-situ replacement to humanize antibody gene loci while preserving the mouse Fc region and normal immune system development. This capability underpins the RenMice platform family — RenMab® (monoclonal antibodies), RenLite® (bispecific antibodies with common light chain), RenLite® BsADC (bispecific ADCs with 200+ TAA targets), RenNano® (HCAb/VHH antibodies for tissue-penetrating and CAR-T applications), RenTCR mimic™ (TCR-mimic antibodies targeting intracellular antigens via HLA complexes), and a GPCR-targeted platform. The company has built a 1M+ fully human antibody sequence library covering 1,000+ druggable targets, a catalog of 5,000+ off-the-shelf animal and cell line models, and a track record of 5,500+ customized models, 8,600+ drug evaluation projects, and 350+ fully human antibody collaborations.

Biocytogen operates a multi-stream revenue model combining one-time and perpetual licensing of off-the-shelf animal and cell models, project-based professional services for customized gene editing and preclinical pharmacology (in vivo efficacy, PK/PD, in vitro pharmacology, non-GLP toxicology), and licensing/royalty arrangements for collaborative fully human antibody discovery and preclinical asset partnerships. The go-to-market is enterprise field sales with dedicated scientific account managers, supported by scientific publications, industry conferences, and direct partner engagement. Named customers include Alexion Pharmaceuticals, Be Biopharma (since 2021, multi-model rare-disease collaboration), and Massachusetts General Hospital. The company holds AAALAC International accreditation for animal care and use programs.

Name

北京百奥赛图基因生物技术有限公司

Legal name

北京百奥赛图基因生物技术有限公司

Website

https://bbctg.com.cn

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Beijing Biocytogen is a preclinical drug discovery platform leveraging proprietary SUPCE™ gene editing and RenMice humanized mouse platforms to deliver fully human antibody discovery, gene-edited animal models, and integrated pharmacology services to global pharmaceutical and biotechnology clients.

Ownership category

akta.pro rank

Product category

Preclinical Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Preclinical drug discovery
• Gene editing services
• Humanized mouse models
• Antibody discovery platforms
• Pharmacology efficacy studies

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Animal and Cell Line Models: Sale of off-the-shelf and customized gene-humanized mouse models, immunodeficient models, tool mice, knockout models, aged mice, disease model mice, and cell lines for preclinical drug evaluation.
2. Gene Editing Services: Customized gene editing services including conventional knockout/knockin, conditional knockout/knockin, point mutation knockin, Rosa26 locus knockin, Tag & Reporter genes, and Tol2 transgenic mouse models.
3. Pharmacology and Efficacy Services: In vivo pharmacology, PK/PD studies, in vitro pharmacology, and Non-GLP toxicology research services for drug efficacy and safety evaluation.
4. Fully Human Antibody Discovery Collaboration: Collaborative antibody discovery projects using RenMice platforms for pharmaceutical and biotech partners seeking fully human antibody candidates.
5. Preclinical Asset Partnership: Licensing and partnership of preclinical drug assets including bispecific antibodies, ADCs, TAA antibodies, Hu-VHH antibodies, TCR mimic antibodies, and autoimmune disease assets.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Biocytogen provides integrated preclinical drug discovery products and services centered on its proprietary SUPCE™ gene editing technology and RenMice platform family (RenMab®, RenLite®, RenNano®, RenTCR mimic™). The company sells over 5,000 off-the-shelf and customized humanized, immunodeficient, knockout, disease, and aged mouse models plus cell lines, while delivering gene editing services, in vivo/in vitro pharmacology, PK/PD, and non-GLP toxicology studies. It also offers fully human antibody discovery collaborations, a 1M+ antibody sequence library, and preclinical asset out-licensing for bispecifics, ADCs, TCR-mimics, and autoimmune candidates.

Product overview

Biocytogen operates as an integrated biopharmaceutical technology platform offering preclinical drug discovery services and fully human antibody development solutions. The core portfolio centers on the RenMice antibody discovery engine family (RenMab®, RenLite®, RenNano®, RenTCR mimic™), which enables fully human antibody generation through proprietary SUPCE™ gene editing technology. The company provides over 5,000 off-the-shelf animal and cell models, including gene-humanized, immunodeficient, disease-specific, and aged mouse models, complemented by comprehensive preclinical services (gene editing, in vivo/in vitro pharmacology, PK/PD, and non-GLP toxicology). The technology platform extends to bispecific antibodies, bispecific ADCs, TCR-mimic antibodies, and GPCR antibody platforms. The business model integrates target validation, fully human antibody discovery, preclinical pharmacology, and IND-enabling studies to support drug development from targets to therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• 百奥动物 (BioMice): 子品牌百奥动物BioMice，拥有数千种现成的药物靶点人源化动物/细胞模型，为评估药物药效、安全性和机制研究提供可靠的解决方案。

Products and services

• RenMab® Monoclonal Antibody Discovery Platform Monoclonal antibody discovery platform using gene-humanized mice with target KO strategy, offering high diversity and affinity, novel binding epitopes, and multi-species cross-reactivity for pharmaceutical and biotech partners developing therapeutic mAbs.
• RenLite® Bispecific Antibody Platform Bispecific antibody discovery platform with common light chain technology enabling easy assembly, high purity, and excellent developability for partners developing bispecific therapeutics.
• RenNano® Hu-VHH Single-Domain Antibody Platform Humanized VHH (Hu-VHH) antibody discovery platform offering excellent tissue permeability, suitable for assembling bispecific/multispecific antibodies and CAR-T applications.
• RenTCR mimic™ TCR-Mimic Antibody Platform TCR-mimic antibody platform that targets intracellular antigens with high specificity for target HLA complexes, enabling access to intracellular targets traditionally considered undruggable.
• Bispecific Antibody-Drug Conjugate (BsADC) Platform Bispecific ADC platform with 200+ TAA targets, offering enhanced efficacy and reduced toxicity for partners developing next-generation antibody-drug conjugates.
• Anti-GPCR Antibody Platform Antibody discovery platform for difficult targets including multi-pass transmembrane GPCR proteins, addressing historically challenging receptor classes for antibody therapeutics.
• Fully Human Antibody Library Library of over 1 million fully human antibody sequences covering 1,000+ druggable targets, offered for antibody drug discovery collaborations and licensing to pharmaceutical and biotech partners.
• Gene-Humanized Mouse Models Humanized mouse models with human gene knock-in for drug target validation and antibody efficacy testing, offered off-the-shelf and as customized models under the BioMice sub-brand.
• Immunodeficient Mouse Models Immunodeficient mouse models including B-NDG variants for xenograft studies and human cell transplantation, supplied off-the-shelf to research and preclinical programs.
• Knockout (KO) Mouse Models Conventional and conditional knockout mouse models for gene function studies, available as off-the-shelf catalog items or customized generation projects.
• Tool Mouse Models Genetically modified tool mice for research applications, including conditional gene expression systems such as Cre/lox and reporter lines.
• Aged Mouse Models Aged mouse models for age-related disease research and geriatric drug testing, supplied as a ready-to-use catalog product.
• Pre-validated Disease Mouse Models Pre-established disease mouse models covering oncology, autoimmune diseases, metabolic disorders, and neuroscience indications, available as off-the-shelf disease models for therapeutic evaluation.
• Cell Lines Ready-to-use cell lines for drug screening, PK/PD studies, and in vitro pharmacology, supplied as catalog products to research and preclinical teams.
• Gene Editing Services Custom gene editing services including conventional knockout/knock-in, conditional knockout/knock-in, point mutation knock-in, Rosa26 locus knock-in, Tag & Reporter genes, and Tol2 transgenic mouse model generation.
• In Vivo Pharmacology Services In vivo efficacy studies conducted in humanized or disease model animals for therapeutic candidate evaluation across oncology, autoimmune, metabolic, and neuroscience indications.
• PK/PD Studies Pharmacokinetics and pharmacodynamics studies for drug disposition and target engagement assessment in preclinical species.
• In Vitro Pharmacology Services In vitro pharmacological assays including binding studies, functional assays, and mechanism of action investigations for drug candidate characterization.
• Non-GLP Toxicology Studies Non-GLP toxicology studies for preclinical safety assessment of drug candidates, supporting IND-enabling safety packages.
• Colony Management and Breeding Services Colony management and breeding services supporting maintenance, expansion, and genetic quality of client-purchased or customized animal models.

Quantifiable outcome

• 350+ fully human antibody collaboration projects completed
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Be BiopharmacoreStrategic or Co-development Partner · 1 January 2021Since 2021, Biocytogen has collaborated with Be Biopharma to develop five different B-NDG hIL6 models supporting Be Bio's rare disease drug pipeline including Fabre, MPS-IV, Niemann Pick A/B, Hemophilia B, and Hypophosphatasia. Be Biopharma views Biocytogen's capabilities as complementary to their own, with the partnership enabling leverage of mutual strengths for current and future drug development programs.
• Alexion PharmaceuticalscoreStrategic or Co-development PartnerBiocytogen provides Genomic Medicine Preclinical Pharmacology services to Alexion Pharmaceuticals. Principal Scientist Dr. Joy Wang expressed sincere gratitude for the invaluable collaboration, noting that Biocytogen's support and dedication significantly contributed to project timelines.
• Massachusetts General Hospital (MGH)minorStrategic or Co-development PartnerDr. Zhongcong Xie, Director of Geriatric Anesthesia Research Unit at MGH, utilizes Biocytogen's gene targeting services for basic science research. The services are described as professional, efficient, and productive, helping achieve research goals.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Crown Bioscience: Preclinical CRO specializing in oncology and metabolic disease animal models, in vivo pharmacology and translational research. Closely comparable to Biocytogen's disease model catalog (oncology, autoimmune, metabolic, neuroscience) and in vivo efficacy services.
• Adimab: Yeast display-based antibody discovery platform providing fully human antibody leads and optimization to pharma partners. Direct competitor to Biocytogen's antibody discovery franchises with overlapping enterprise customer base in big pharma.
• GenScript ProBio: Biologics CRO/CDMO offering antibody discovery, cell line engineering, gene editing and preclinical services. Overlaps directly with Biocytogen on antibody discovery, gene synthesis/editing services and preclinical pharmacology for global pharma and biotech clients.
• AbCellera Biologics: Antibody discovery platform combining single-cell sequencing, display technologies and AI to deliver fully human therapeutic antibodies to pharma partners. Directly comparable to Biocytogen's RenMice-based fully human antibody discovery business and target the same biotech/pharma outsourcing customer base.
• Cyagen Biosciences: Gene editing and animal model provider offering custom mouse model generation, cell line engineering and preclinical research services. Direct overlap with Biocytogen's gene editing services and gene-humanized/knockout model catalog.
• Taconic Biosciences: Supplier of genetically engineered mouse and rat models including humanized, knockout and disease models for research and preclinical use. Directly comparable to Biocytogen's BioMice catalog and gene-humanized model portfolio, particularly for pharma and academic buyers.

Broad incumbents

• Pharmaron: China-rooted global CRO offering drug discovery, preclinical and CMC services with a biologics arm. Comparable to Biocytogen on integrated preclinical offerings and China-based operations serving Western pharma, although with a broader small-molecule orientation.
• Regeneron Pharmaceuticals: Owns VelocImmune, a humanized-mouse antibody platform that pioneered fully human antibody generation, and uses it both internally and via the Regeneron Antibody Discovery agreement framework. A scaled incumbent whose platform philosophy (humanized mice → therapeutic antibodies) is the closest large-cap analogue to Biocytogen's SUPCE/RenMice stack.
• WuXi Biologics: Global end-to-end biologics discovery, development and manufacturing organization with significant antibody discovery and preclinical capability. Competes for the same large-pharma outsourcing wallet and benefits from similar China-based cost economics, making it a key incumbent peer.
• Charles River Laboratories: Large preclinical CRO with extensive animal model, safety assessment and discovery services portfolios. Comparable on the preclinical services side (in vivo pharmacology, toxicology, research models) although less specialized in antibody discovery than Biocytogen.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/%E5%8C%97%E4%BA%AC%E7%99%BE%E5%A5%A5%E8%B5%9B%E5%9B%BE%E5%9F%BA%E5%9B%A0%E7%94%9F%E7%89%A9%E6%8A%80%E6%9C%AF%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 北京百奥赛图基因生物技术有限公司